Literature DB >> 27632986

Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.

Katherine N Gharibian1, Venkatesh L Murthy2, Bruce A Mueller3.   

Abstract

BACKGROUND: Regadenoson is a novel pharmacological stress agent whose disposition during hemodialysis is not known. The purpose of this study was to determine the clearance of regadenoson under varying dialytic conditions using an in vitro hemodialysis model. METHODS AND
RESULTS: Whole human blood was used to analyze the effect of hemodialysis on the clearance of regadenoson. Regadenoson transmembrane clearance (CLD) was assessed for both a standard permeability and a high permeability polysulfone hemodialyzer with blood/dialysate flow rates of 300/600 and 400/800 mL/min. A two-tailed, paired Student's t test was used to compare regadenoson CLD between hemodialyzer types and flow rates. The mean ± SD regadenoson CLD values ranged between 62.5 ± 11.8 and 89.1 ± 24.0 mL/min for all dialytic conditions. There was no significant difference in regadenoson CLD between hemodialyzer types and flow rates (p > .05).
CONCLUSIONS: Hemodialysis enhances the clearance of regadenoson independent of hemodialyzer permeability and blood/dialysate flow rate. This clearance is modest relative to total body clearance and is unlikely to produce a clinically significant outcome.

Entities:  

Keywords:  Regadenoson; chronic kidney disease (CKD); clearance; hemodialysis

Mesh:

Substances:

Year:  2016        PMID: 27632986     DOI: 10.1007/s12350-016-0667-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  28 in total

1.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

2.  Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers.

Authors:  Mridula Rai; Alan W Ahlberg; Julianna Marwell; Waseem Chaudhary; John A Savino; Eric L Alter; Milena J Henzlova; W Lane Duvall
Journal:  J Nucl Cardiol       Date:  2016-02-22       Impact factor: 5.952

3.  Regadenoson induced acute ST-segment elevation myocardial infarction and multivessel coronary thrombosis.

Authors:  David H Hsi; Rajeev Marreddy; Mark Moshiyakhov; Ulrich Luft
Journal:  J Nucl Cardiol       Date:  2013-03-05       Impact factor: 5.952

Review 4.  Noninvasive stress testing for coronary artery disease.

Authors:  Todd D Miller; J Wells Askew; Nandan S Anavekar
Journal:  Cardiol Clin       Date:  2014-08       Impact factor: 2.213

5.  Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve.

Authors:  Nils P Johnson; K Lance Gould
Journal:  JACC Cardiovasc Imaging       Date:  2011-09

6.  Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.

Authors:  Maria Octavia Rangel; Raysa Morales Demori; Sarah T Voll; Marwan Wassouf; Rizcallah Dick; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2014-12-11       Impact factor: 5.952

7.  Ertapenem clearance during modeled continuous renal replacement therapy.

Authors:  J M Stevenson; J H Patel; M D Churchwell; A M Vilay; D D Depestel; F Sörgel; M Kinzig; V Jakob; B A Mueller
Journal:  Int J Artif Organs       Date:  2008-12       Impact factor: 1.595

Review 8.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

9.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

Review 10.  Regadenoson in the detection of coronary artery disease.

Authors:  Christiane Buhr; Mario Gössl; Raimund Erbel; Holger Eggebrecht
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  5 in total

1.  Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient.

Authors:  Ankur Gupta; Navkaranbir S Bajaj
Journal:  J Nucl Cardiol       Date:  2017-08-14       Impact factor: 5.952

Review 2.  Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.

Authors:  Aviral Vij; Yasmeen Golzar; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2017-06-26       Impact factor: 5.952

3.  Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Curr Cardiovasc Imaging Rep       Date:  2017-03-18

4.  The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.

Authors:  Ahmed A Kolkailah; Mina Iskander; Fady Iskander; Priya P Patel; Rozi Khan; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2020-07-06       Impact factor: 5.952

5.  Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an In Vitro hemodialysis model.

Authors:  Sagar U Nigwekar; Amy Barton Pai; Bruce Mueller; Michael C Dean; Gabrielle Costello; Craig R Sherman
Journal:  PLoS One       Date:  2019-11-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.